189 related articles for article (PubMed ID: 15690207)
1. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario.
Astolfi A; Rolla S; Nanni P; Quaglino E; De Giovanni C; Iezzi M; Musiani P; Forni G; Lollini PL; Cavallo F; Calogero RA
Cancer Immunol Immunother; 2005 Jun; 54(6):599-610. PubMed ID: 15690207
[TBL] [Abstract][Full Text] [Related]
2. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of Flt-3 ligand gene ablates tumor immunity elicited by HER-2/neu DNA vaccine in transgenic mice.
Venanzi FM; Barucca A; Havas K; Capitani M; Provinciali M; Scotti S; Concetti A
Vaccine; 2010 May; 28(22):3841-7. PubMed ID: 20350624
[TBL] [Abstract][Full Text] [Related]
4. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.
Croci S; Recktenwald CV; Lichtenfels R; Nicoletti G; Dressler SP; De Giovanni C; Astolfi A; Palladini A; Shin-ya K; Landuzzi L; Nanni P; Lollini PL; Seliger B
Proteomics; 2010 Nov; 10(21):3835-53. PubMed ID: 20957756
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
6. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
[TBL] [Abstract][Full Text] [Related]
7. In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging.
Provinciali M; Barucca A; Pierpaoli E; Orlando F; Pierpaoli S; Smorlesi A
Cancer Immunol Immunother; 2012 Mar; 61(3):363-71. PubMed ID: 21922332
[TBL] [Abstract][Full Text] [Related]
8. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
[TBL] [Abstract][Full Text] [Related]
9. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins.
Quaglino E; Mastini C; Amici A; Marchini C; Iezzi M; Lanzardo S; De Giovanni C; Montani M; Lollini PL; Masucci G; Forni G; Cavallo F
Cancer Res; 2010 Apr; 70(7):2604-12. PubMed ID: 20332241
[TBL] [Abstract][Full Text] [Related]
10. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
Amici A; Smorlesi A; Noce G; Santoni G; Cappelletti P; Capparuccia L; Coppari R; Lucciarini R; Petrelli C; Provinciali M
Gene Ther; 2000 Apr; 7(8):703-6. PubMed ID: 10800094
[TBL] [Abstract][Full Text] [Related]
11. Immunological prevention of a multigene cancer syndrome.
Croci S; Nicoletti G; Landuzzi L; De Giovanni C; Astolfi A; Marini C; Di Carlo E; Musiani P; Forni G; Nanni P; Lollini PL
Cancer Res; 2004 Nov; 64(22):8428-34. PubMed ID: 15548714
[TBL] [Abstract][Full Text] [Related]
12. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
[TBL] [Abstract][Full Text] [Related]
14. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity.
Spadaro M; Ambrosino E; Iezzi M; Di Carlo E; Sacchetti P; Curcio C; Amici A; Wei WZ; Musiani P; Lollini PL; Cavallo F; Forni G
Clin Cancer Res; 2005 Mar; 11(5):1941-52. PubMed ID: 15756020
[TBL] [Abstract][Full Text] [Related]
15. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.
Koman IE; Commane M; Paszkiewicz G; Hoonjan B; Pal S; Safina A; Toshkov I; Purmal AA; Wang D; Liu S; Morrison C; Gudkov AV; Gurova KV
Cancer Prev Res (Phila); 2012 Aug; 5(8):1025-35. PubMed ID: 22689915
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.
De Giovanni C; Nicoletti G; Landuzzi L; Croci S; Palladini A; Antognoli A; Murgo A; Ianzano ML; Grosso V; Stivani V; Iezzi M; Musiani P; Nanni P; Lollini PL
Vaccine; 2009 Mar; 27(14):2065-9. PubMed ID: 19428831
[TBL] [Abstract][Full Text] [Related]
17. In silico modeling and in vivo efficacy of cancer-preventive vaccinations.
Palladini A; Nicoletti G; Pappalardo F; Murgo A; Grosso V; Stivani V; Ianzano ML; Antognoli A; Croci S; Landuzzi L; De Giovanni C; Nanni P; Motta S; Lollini PL
Cancer Res; 2010 Oct; 70(20):7755-63. PubMed ID: 20924100
[TBL] [Abstract][Full Text] [Related]
18. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
19. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance.
Ambrosino E; Spadaro M; Iezzi M; Curcio C; Forni G; Musiani P; Wei WZ; Cavallo F
Cancer Res; 2006 Aug; 66(15):7734-40. PubMed ID: 16885376
[TBL] [Abstract][Full Text] [Related]
20. Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells.
Croci S; Nicoletti G; Landuzzi L; Palladini A; Chiarini F; Nanni P; Lollini PL; De Giovanni C
Oncol Rep; 2007 Aug; 18(2):451-6. PubMed ID: 17611670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
